Hippocratic AI, a healthcare-focused AI company, has raised $141 million in a Series B funding round led by Kleiner Perkins, bringing its valuation to $1.64 billion. This marks a significant milestone in the company’s mission to enhance patient care and operational efficiency through safety-focused AI agents. Existing investors, including NVIDIA, General Catalyst, and A16z, also participated, bringing the company’s total funding to $278 million. Hippocratic AI aims to address non-diagnostic, patient-facing healthcare challenges by empowering clinicians with secure, impactful AI solutions that allow more time for direct patient care.
The company plans to use the funds to expand into pharmaceuticals, payer markets, and regions such as EMEA, Latin America, and Southeast Asia. A major initiative tied to this funding is the launch of the AI Agent App Store, where clinicians can co-develop tailored AI agents for specific healthcare tasks in under 30 minutes. These agents are rigorously safety-tested to ensure practical applicability in real-world healthcare environments. By integrating clinician expertise into its AI solutions, Hippocratic AI is poised to transform healthcare delivery while maintaining a strong focus on safety, collaboration, and global expansion.